2 Thumbs Up for Mesoblast, page-41

Cat-o

Thats plain nonsense. What's the benchmark survival rate now? Isn't it ~10%?

So lets use that as a fair and reasonable benchmark, its slightly less.

• 83% is a x8 multiplier
• 54% is a x5 multipler
• 44% is a x4 multipler
• 39% is a x3 multiplier

If we are conservative and take your 44% survival scenario, people have more than a 400% better chance of surviving than the benchmark.

You reckon, based on that quantum leap in survival rate, thats worth a 36% DROP in share price... emmmm something doesn't smell right here!

We sat a peak of @3.21 before the COVID19 event on the basis of the current product pipeline and their respective lifecycle, and have had significant free globalmarketing (typically worth millions of dollars) in an acutely pandemic aware political, financial and social environment, with governments looking for a silver bullet of some magnitude; FDA approval on that percentage increase would be certain, and in particular given the likelyhood of zero material secondary impacts to patient health.

The price is not currently sitting at optimistic levels for COVID19.... sentiment still has a good element of risk factored in, which is why its not near its peak at 4.45.

LMAO... you're the best!